ClinicalTrials.gg
RecruitingNCT06351527Updated Jun 19, 2025

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

A Phase 1 interventional study of ICP-248 and Obinutuzumab (G) in Mature B-cell Malignancies, sponsored by InnoCare Pharma Inc.. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by InnoCare Pharma Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies

02

Conditions studied

  • Mature B-cell Malignancies
03

In context

Lead sponsor

InnoCare Pharma Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Age ≥ 18.
  2. Subjects with histopathologically and/or flow cytometry-confirmed diseases according to the 2016 World Health Organization (WHO) classification criteria for lymphohematopoietic neoplasms or meeting the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria: CLL/SLL, relapsed or refractory MCL. Patients must have received at least two prior lines of adequate systemic therapy before study entry, and at least one prior systemic therapy should include Bruton's kinase inhibitor (BTKi).
  3. For subjects with R/R MCL: Patients must have per the Lugano 2014 criteria.
  4. Patients with an (ECOG) performance status (PS) score of ≤ 1 and a of ≥ 6 months.
  5. Adequate hematologic, hepatic, renal, pulmonary and cardiac function
  6. Patients with basically normal coagulation function
  7. Patients with fertility potential and their partners need
  8. Subjects can communicate with the investigator well and to complete the study as specified in the study.

Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma/leukemia.
  2. Known or suspected history of Richter's transformation.
  3. Prior stem cell transplant (unless ≥ 3 months since transplant); or prior chimeric cell therapy (unless ≥ 3 months since cell infusion).
  4. A history of allogeneic stem cell transplantation.
  5. An interval of less than 5 half-lives from the last dose of a strong or CYP2C8 inhibitor or inducer (chemical agent, herbal medicine and dietary supplement) to the first dose of the product, or a plan to use concurrently medications, dietary supplements or food (e.g., grapefruit or grapefruit juice) with strong CYP3A or CYP2C8 inhibitory or inductive effect during study participation
  6. Presence of active infection that currently requires intravenous systemic anti-infective therapy.
  7. History of immunodeficiency, including a positive (HIV) antibody test.
  8. History of significant cardiovascular disease
  9. Patients with previous or concomitant central nervous system disorders
  10. Grade 2 or above toxicity due to prior anti-cancer therapy at screening
  11. Known alcohol or drug dependence
  12. Unable to swallow tablets or presence of disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Dose-Escalation Cohort - CLL/SLL and MCL

    Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose. Cycles will comprise 28 days.

    Drug: ICP-248

  • Experimental
    Dose-Expansion Cohort A - CLL/SLL

    Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose and obinutuzumab for 6 cycles. Cycles will comprise 28 days.

    Drug: ICP-248 · Drug: Obinutuzumab (G)

  • Experimental
    Dose-Expansion Cohort B - MCL

    Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose. Cycles will comprise 28 days.

    Drug: ICP-248

  • Experimental
    Dose-Expansion Cohort C - MCL

    Participants will receive ICP-248 daily from an initial dose of 5/10 mg to the target dose and Rituximab for 18 cycles. Cycles will comprise 28 days.

    Drug: ICP-248 · Drug: Rituximab (R)

Interventions

  • ICP-248 will be administered orally once daily at escalated doses (starting dose 5/10 mg, maximum 150 mg).

  • Obinutuzumab will be administered by IV infusion at a dose of 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6.

  • Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) at Day 1 per week for 4 weeks during cycle 1, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years.

06

What researchers measure

Primary outcomes

  1. DLT

    Dose-limiting toxicity (DLT) rate at each dose level DLT will be assessed via CTCAE version 5.0 or iwCLL 2018.

    Time frame: 49 days

  2. Safety and tolerability of ICP-248 at different doses in B-cell malignancies

    To investigate the incidence, nature and severity of adverse events (AE) according to NCI-CTCAE V5.0 evaluation criteria or iwCLL 2018.

    Time frame: 5 years

Secondary outcomes

  1. Cmax, ss of ICP-248

    Steady State Maximum Concentration of ICP-248

    Time frame: Predose up to week 28

  2. Ctrough, ss of ICP-248

    Steady State Trough Concentration of ICP-248

    Time frame: Predose up to week 28

  3. Preliminary efficacy of ICP-248 monotherapy in patients with B-cell malignancy

    Investigator-assessed ORR and CRR as defined by the Lugano 2014 Classification or per iwCLL 2018 criteria

    Time frame: 5 years

07

Study locations

8 of 8 sites recruiting
  • BRCR Medical Center
    Plantation, Florida 33322, United States
    Recruiting
    • BRCR Medical Center · Contact
  • Clinical Research Alliance
    Westbury, New York 11590, United States
    Recruiting
    • Clinical Research Alliance · Contact
  • Pan American Center for Oncology Trials
    San Juan, 00935, Puerto Rico
    Recruiting
    • Pan American Center for Oncology Trials · Contact
  • CNE CCOHTPC of Cherkasy Regional Council
    Cherkasy, 18009, Ukraine
    Recruiting
    • CNE CCOHTPC of Cherkasy Regional Council · Contact
  • CNE"City Clin Hosp#4"of Dnipro City Council
    Dnipro, 49102, Ukraine
    Recruiting
    • CNE CCOHTPC of Cherkasy Regional Council · Contact
  • Medical Center of Limited Liability Company Arensia Exploratory Medicine
    Kyiv, 1135, Ukraine
    Recruiting
    • Medical Center of Limited Liability Company Arensia Explorator · Contact
  • Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC
    Kyiv, 2091, Ukraine
    Recruiting
    • Med Center 'Ok!Clinic+' of International Institute of Clinical · Contact
  • SI Institute of Blood Pathology and Transfusion Medicine of AMSU
    Lviv, 79057, Ukraine
    Recruiting
    • SI Institute of Blood Pathology and Transfusion Medicine of AM · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jun 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartActual
Apr 23, 2024
Primary completionEst.
Jun 25, 2027
CompletionEst.
Oct 25, 2027
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06351527
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Apr 23, 2024
Primary completion
Jun 25, 2027 (estimated)
Completion
Oct 25, 2027 (estimated)
Last update
Jun 19, 2025

Study contacts

Study Director
Contact
ICP-CL-1202general@innocarepharma.com
609-524-1106

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesutoclax

Start the discussion